Results 31 to 40 of about 20,060 (180)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population

Kidney & Blood Pressure Research, 2015
Background/Aims: Hepatitis C virus infection remains prevalent among patients undergoing long-term haemodialysis and has a detrimental impact on survival in this population.
Mario Espinosa, Jesùs Hernàndez, Maria Dolores Arenas, Fernando Carnicer, Carlos Caramelo, Fabrizio Fabrizi   +5 more
doaj   +1 more source

Interferons lambda – therapeutic application

Сибирский научный медицинский журнал, 2020
Interferons are a group of protein molecules with a broad spectrum of effects on the human body. Interferon lambda (type III interferon) was discovered comparatively recently about 20 years ago and its action is still poorly understood.
N. A. Kikhtenko, L. A. Oleynik, V. K. Makarov, E. P. Nagorskaya, P. G. Madonov   +4 more
doaj   +1 more source

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin

Annals of Hepatology, 2010
The effect of interferon alfa against hepatitis C virus has been well documented. However, clinical efficacy is low due to the short interferon residence in the body.
Ricardo Jiménez-Méndez, Gilberto Castañeda-Hernández   +1 more
doaj   +1 more source

Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review

Revista do Instituto de Medicina Tropical de São Paulo, 2019
Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment ...
Marcos Mucenic, Ajacio Bandeira de Melo Brandão, Claudio Augusto Marroni, Alfeu de Medeiros Fleck Junior, Maria Lucia Zanotelli, Ian Leipnitz, Mário Henrique Meine, Guillermo Kiss, Juliano Martini, Eduardo Soares Schlindwein, Ane Micheli Costabeber, Fernanda Karlinsky Rodrigues Sacco, Giovana Rossato, Guido Pio Cracco Cantisani   +13 more
doaj   +1 more source

Evaluation of the long-term outcomes of patients with hepatitis delta

Journal of Infection in Developing Countries
Objective: To evaluate the long-term outcomes of hepatitis delta patients, including cirrhosis and hepatocellular carcinoma (HCC), based on clinical and laboratory data.
Muhammet Salih Tarhan, Habip Gedik, Kadriye Kart-Yasar   +2 more
doaj   +1 more source

[Pegylation and interferons in multiple sclerosis]

Farmeconomia. Health economics and therapeutic pathways, 2016
Pegylation is a procedure used for drug development since the 1970s and consists of the conjugation of a polyethylene glycol molecule (PEG) to a drug. PEG has shown to be safe and effective in improving the pharmacokinetic and pharmacodynamic profile of drugs.
Cecilia Saleri, Diego Centonze, Giulia Vestri, Elisa Puma, Sergio Iannazzo, Luigi Giuliani, L Santoni, Pier Luigi Canonico   +7 more
openaire   +4 more sources

Validation of a questionnaire to monitor symptoms in HIV-infected patients during hepatitis C treatment

AIDS Research and Therapy, 2017
Background Clinicians are incorporating patient-reported outcomes in the management of HIV-infected persons co-infected with hepatitis C virus (HCV), but there are no validated inventories to monitor symptoms of patients during HCV therapy.
Edward R. Cachay, Craig Ballard, Bradford Colwell, Francesca Torriani, Charles Hicks, Wm. Christopher Mathews   +5 more
doaj   +1 more source

Nano‐Enabled Systemic Delivery of STING Agonist by Engineered Silicasome for Potent Antitumor Immunotherapy

Advanced Science, EarlyView.
Engineered mesoporous silica nanoparticles (Silicasomes) enable systemic delivery of the STING agonist ADU‐S100, overcoming the instability and toxicity that limit cyclic dinucleotides to local administration. By enhancing tumor accumulation, activating systemic antitumor immunity, and remodeling the tumor immune microenvironment, these nanoparticles ...
Wenjing Zhou, Yuting Li, Xudong Sun, Honghong Yang, Xiayu Shi, Lijia Yao, Jinhong Jiang, Erli Wang, Haoyang Wang, Yi Wei, Xiangsheng Liu   +10 more
wiley   +1 more source

Response to pegylated interferon in a COVID‐19 positive male with metastatic jejunal neuroendocrine tumor treated with everolimus

Clinical Case Reports, 2021
A 61‐year‐old male on everolimus had chronic SARS‐CoV‐2 infection. Addition of pegylated interferon cleared viral RNA and supports combination therapy with everolimus plus interferon for COVID‐19.
Arthur E. Frankel, Wai C. Yip, Eknath Naik, Hans C. Hasselbalch   +3 more
doaj   +1 more source

Decoding Undesirable Inflammatory Responses of Nucleic Acid‐Delivering Lipid Nanoparticles

Advanced Science, EarlyView.
Lipid nanoparticles (LNPs) enable efficient nucleic acid delivery, but their immunogenicity is a double‐edged sword. This review explores LNP‐driven innate and adaptive immunity, covering lipid components, endosomal escape, and nucleic acid sensing.
Ruimin Hu, Yin Dou, Chenwen Li, Yuying Mu, Huiying Ouyang, Wenhao Shen, Jianxiang Zhang   +6 more
wiley   +1 more source